SHR4597

Phase 2Small molecule

Guangdong Hengrui Pharmaceutical Co., Ltd

SHR4597 is one of 26 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaNot yet recruiting

AsthmaPhase 2

Not yet recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Arcoxia

Novartis

Preclinical

—3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 4

DUPIXENT

Regeneron

Preclinical

1 5

Paracetamol

GSK

Preclinical

1 6

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 7

SHR4597

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 2

1 8

Aclidinium Bromide

Atrovent

2 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma1 trial

Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma

Not yet recruiting· Guangdong Hengrui Pharmaceutical Co., Ltd logo

Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT06940700·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SHR4597. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR4597 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR4597. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Hengrui Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Guangdong Hengrui Pharmaceutical Co., Ltd

SHR4597

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma1 trial

References

Drug Info

Quick Facts

Related News